Loading organizations...
§ Private Profile · Changping, Beijing, China
Long-read sequencing services for genomic research, pathogen detection, and clinical testing using proprietary bioinformatics.
GrandOmics, based in Beijing, China, applies long-read sequencing technology for genomic research, pathogenic microorganism detection, and clinical testing services using proprietary bioinformatics software. The company specializes in third-generation sequencing for genome and transcriptome analysis, including single-cell transcriptomics, and provides nanopore sequencing services worldwide, such as the Personal Reference Genome Project. Recognized as the world's largest third-generation sequencing application company, GrandOmics operates 20 GridIONs and 1 PromethION, having achieved 96 whole-genome sequencing projects in 96 hours generating 7.6 Tb of data. The company has raised a total of $29 million in funding, including a $15 million Series B round, with investors such as MPC, Marathon Venture Partners, and SAIF Partners China. GrandOmics also partners with Oxford Nanopore Technologies, notably on the dbSV100K project to analyze 100,000 human genomes. It was founded in 2011 by Depeng Wang.
GrandOmics has raised $15.3M across 1 funding round.
GrandOmics has raised $15.3M in total across 1 funding round.
GrandOmics has raised $15.3M across 1 funding round. Most recently, it raised $15.3M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2021 | $15.3M Series B | Yuan YI Capital | YU Zhiyun | Announced |
GrandOmics has raised $15.3M in total across 1 funding round.
GrandOmics's investors include Yuan Yi Capital, Yu Zhiyun.